Amgen (AMGN) EVP Reese reports 1,433-share tax-withholding disposition at $329.82

Rhea-AI Filing Summary

Amgen Inc. executive David M. Reese reported routine tax-related share dispositions. On May 2, 2026, a total of 1,433 shares of Amgen common stock were withheld at $329.82 per share to cover tax obligations, classified as tax-withholding dispositions rather than open-market sales.

A footnote notes that the reported holdings include 442 Dividend Equivalents tied to unvested Restricted Stock Units, which will be paid in common shares on a one-to-one basis as those units vest.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider REESE DAVID M

Role EVP & Chief Technology Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	746	$329.82	$246K
Tax Withholding	Common Stock	687	$329.82	$227K

Holdings After Transaction: Common Stock — 41,041 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Tax-withholding shares: 1,433 shares Tax-withholding price: $329.82 per share First withholding lot: 687 shares +2 more

5 metrics

Tax-withholding shares 1,433 shares Total common shares withheld for tax obligations on May 2, 2026

Tax-withholding price $329.82 per share Price applied to both tax-withholding dispositions

First withholding lot 687 shares Common stock withheld in first F-code transaction

Second withholding lot 746 shares Common stock withheld in second F-code transaction

Dividend Equivalents 442 units Dividend Equivalents credited to unvested RSUs, payable in stock

Key Terms

tax-withholding disposition, Dividend Equivalents, Restricted Stock Units, Equity Incentive Plan

4 terms

tax-withholding disposition financial

"classified as tax-withholding dispositions rather than open-market sales"

A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.

Dividend Equivalents financial

"These shares include 442 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc."

Payments tied to employee or contractor equity awards that mirror the cash dividends paid on the company’s stock; they give the holder the same economic benefit as owning the shares without transferring actual shares—often paid in cash or additional award units when the award becomes payable. Investors care because these payments affect a company’s compensation costs, cash flow and potential share dilution, and they signal how management is being rewarded and aligned with shareholders.

Restricted Stock Units financial

"DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Equity Incentive Plan financial

"granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

REESE DAVID M

(Last) (First) (Middle)

ONE AMGEN CENTER

DRIVE

(Street)

THOUSAND OAKS CALIFORNIA 91320

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AMGEN INC [ AMGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & Chief Technology Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/02/2026		F		746	D	$329.82	41,041	D
Common Stock	05/02/2026		F		687	D	$329.82	40,354(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares include 442 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

	/s/ David M. Reese	05/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Amgen (AMGN) EVP David M. Reese report on this Form 4?

David M. Reese reported tax-withholding dispositions of Amgen common stock. On May 2, 2026, a total of 1,433 shares were withheld at $329.82 per share to satisfy tax obligations, rather than being sold in open-market transactions.

How many Amgen (AMGN) shares were involved in Reese’s tax-withholding transactions?

Two transactions together involved 1,433 Amgen common shares. One withheld 687 shares and the other 746 shares, with both transactions executed at a price of $329.82 per share for tax-liability payments.

Were David M. Reese’s Amgen (AMGN) transactions open-market sales?

No, the transactions were not open-market sales. Both were coded as “F” on the Form 4, meaning shares were withheld by the company to pay tax liabilities, a routine, non-discretionary mechanism rather than a voluntary sale of shares.

What does the Form 4 say about Dividend Equivalents for Amgen (AMGN) shares?

The filing states Reese’s holdings include 442 Dividend Equivalents granted under Amgen’s 2009 Equity Incentive Plan. These are credited to unvested Restricted Stock Units and will be paid in Amgen common stock as the RSUs vest, plus cash for any fractional share amounts.

How are Reese’s Amgen (AMGN) Dividend Equivalents paid out?

Dividend Equivalents are paid out in Amgen common stock on a one-to-one basis as the related Restricted Stock Units vest. In addition, any remaining fractional share amount is settled in cash, following the vesting schedule described in the equity incentive plan.